Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1900E||SWOG||A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1905||SWOG||A Phase I/II Study of AKR1C3-Activated Prodrug OBI‐3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1912CD||SWOG||A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)||Cancer Prevention and Control CIRB||Available to Open|
|S1914||SWOG||A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1922||SWOG||Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI In Refractory Small Bowel Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1925||SWOG||Randomized, Phase II Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1929||SWOG||Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1931||SWOG||Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1933||SWOG||A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1937||SWOG||A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy||Adult CIRB - Late Phase Emphasis||Available to Open|